Febuxostat: Clinical Trials

20 trials of Febuxostat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 2 unknown, 1 active not recruiting. 20 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 320Completed 17, Unknown 2, Active not recruiting 1
Phase 22Completed 1, Unknown 1

Follow Febuxostat: new trials by email Literature Review of Febuxostat trials Research Report on Febuxostat

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tigulixostat (IBI128) vs Febuxostat in Gout
Febuxostat, Tigulixostat - Gout
Phase 3Active not recruitingInnovent Biologics Technology Limited (Shanghai R&D Center)6002026-03-172026-09-01
Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets - Gout With Hyperuricemia in Adults
Phase 3UnknownJiangsu HengRui Medicine Co., Ltd.4342024-06-012024-05-16
Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia
Febuxostat 20MG Tablets, Febuxostat 20MG Placebo, AR882 25MG - Primary Gout, Hyperuricemia
Phase 2 / Phase 3UnknownGuangzhou Ruianbo Pharmaceutical Technology Co., Ltd6362024-04-222024-09-19
Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
HR091506 tablets + placebo of febuxostat tablets, febuxostat tablets + placebo of HR091506 tablets - Gout With Hyperuricemia in Adults
Phase 3CompletedJiangsu HengRui Medicine Co., Ltd.7652023-12-142025-10-02
A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
Epaminurad 6 mg, Epaminurad 9 mg, Febuxostat 40 mg - Gout
Phase 3CompletedJW Pharmaceutical6122023-03-212026-05-04
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With Gout
Dotinurad, Febuxostat, Dotinurad Matched Placebo - Gout
Phase 3CompletedEisai Co., Ltd.4512021-12-212025-07-30
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
FYU-981, Febuxostat - Hyperuricemia With or Without Gout
Phase 3CompletedMochida Pharmaceutical Company, Ltd.2032018-01-092018-09-24
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
Febuxostat, Placebo - Endothelial Dysfunction, Endstage Renal Disease
Phase 2 / Phase 3CompletedAin Shams University572016-08-012018-01-02
Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
Febuxostat IR, Febuxostat XR, Febuxostat placebo - Gout
Phase 3CompletedTakeda17902014-04-012016-11-03
Lesinurad and Febuxostat Combination Extension Study in Gout
lesinurad, febuxostat - Gout
Phase 3CompletedArdea Biosciences, Inc.1962013-03-012018-01-30
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
Febuxostat, Allopurinol - Tumor Lysis Syndrome
Phase 3CompletedMenarini Group3462012-10-012014-11-03
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Lesinurad, Placebo, Febuxostat - Tophaceous Gout
Phase 3CompletedArdea Biosciences, Inc.3302012-01-012016-05-26
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
Febuxostat, Allopurinol - Gout
Phase 3CompletedXijing Hospital5042011-07-012016-02-03
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
febuxostat, Allopurinol - Gout
Phase 3CompletedAstellas Pharma Taiwan, Inc.1092011-03-012014-10-29
Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)
Febuxostat, Allopurinol - Cardiovascular Disease
Phase 3CompletedTakeda61982010-04-232018-06-14
Efficacy and Safety of Oral Febuxostat in Participants With Gout
Febuxostat, Allopurinol - Gout
Phase 3CompletedTakeda22692007-02-012012-02-02
Phase III Trial of Febuxostat in Korea Gout Patients
Febuxostat - Gout
Phase 3CompletedSK Chemicals Co., Ltd.1812006-08-012009-01-13
Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
Febuxostat, Allopurinol - Gout
Phase 3CompletedTakeda10862003-07-012010-07-27
Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Febuxostat, Allopurinol, Placebo - Gout
Phase 3CompletedTakeda10722003-02-012012-02-02
Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Febuxostat, Allopurinol - Gout
Phase 3CompletedTakeda7602002-07-012012-02-02

Conditions studied

Gout (13)  ·  Hyperuricemia (4)  ·  Cardiovascular Diseases (1)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Myocardial Infarction (1)  ·  Stroke (1)  ·  Tumor Lysis Syndrome (1)

Sponsors

Takeda (6)  ·  Ardea Biosciences, Inc. (2)  ·  Jiangsu HengRui Medicine Co., Ltd. (2)  ·  Ain Shams University (1)  ·  Astellas Pharma Taiwan, Inc. (1)  ·  Eisai Co., Ltd. (1)  ·  Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd (1)  ·  Innovent Biologics Technology Limited (Shanghai R&D Center) (1)  ·  JW Pharmaceutical (1)  ·  Menarini Group (1)  ·  Mochida Pharmaceutical Company, Ltd. (1)  ·  SK Chemicals Co., Ltd. (1)  ·  Xijing Hospital (1)

Countries

United States (5)  ·  China (4)  ·  Australia (2)  ·  Canada (2)  ·  New Zealand (2)  ·  Poland (2)  ·  Switzerland (2)  ·  Japan (1)  ·  Mexico (1)  ·  South Korea (1)  ·  Taiwan (1)

Top investigators

Angela Capriati, MD, PhD (1)  ·  Bin Liu, M.D. (1)  ·  Chris Storgard, MD (1)  ·  Haiwang Ji, M.D. (1)  ·  Hong Liu, M.D. (1)  ·  Jianqin Wang, M.D. (1)  ·  Jinying Lin, M.D. (1)  ·  Kazuki Furuno (1)  ·  Michele Spina, MD (1)  ·  Nihar Bhakta, MD (1)  ·  Peng Liu, M.D. (1)  ·  Shenren Chen, M.D. (1)  ·  Won Park, MD (1)

Results publications

PMID 21353107, PMID 22052584, PMID 18600509, PMID 16339094, PMID 18975369, PMID 19286847, PMID 20370912, PMID 21849262, PMID 22132950, PMID 22316106, PMID 22436129, PMID 22795277, PMID 23683134, PMID 26013187, PMID 26216382, PMID 28597604, PMID 29527974, PMID 30073793, PMID 30616614, PMID 35536764, PMID 35835008